BioSpectrum
the business of Bio & Health Sciences
ASIA EDITION

TaiGen filed US IND for its influenza antiviral TG-1000

05 October 2020 | News

This drug has the potential to be a single-dose treatment for influenza

TaiGen Biotechnology Company, Limited ("TaiGen") announced on 5 Oct 2020 that it has filed an Investigational New Drug (IND) application with the US FDA for its influenza antiviral TG-1000.

TG-1000 is a novel pan-influenza antiviral, which interrupts viral replication and transmission *via* a cap-snatching mechanism and is able to do this effectively against influenza-A, influenza-B, avian flu H7N9, and Tamiflu-resistant viruses. The first US patent for TG-1000 was successfully prosecuted and granted by the United States Patent and Trademark Office on Jan 14th, 2020.

A Phase 1 trial for in China was initiated by TaiGen in July 2020 and has successfully completed the first 4 groups in the single ascending dose part. A Phase 2 protocol has also been submitted to the institutional review board (IRB) of China-Japan Friendship Hospital in Beijing last month.

"We are excited about the IND filing in the US for the internally developed TG-1000 which has the potential to be a single dose treatment for influenza," said Kuo-Lung Huang, the Chairman and CEO of TaiGen, "TG-1000 IND filing demonstrates yet again TaiGen's capacity and experience in research and development of NCEs."